Abstract
Autism spectrum disorder (ASD) is a common neurological disorder. Although the etiologies of ASD have been widely speculated, evidence also supports the pathogenic role of cutaneous inflammation in autism. The prevalence of ASD is higher in individuals with inflammatory dermatoses than in those without inflammatory diseases. Anti-inflammation therapy alleviates symptoms of ASD. Recent studies suggest a link between epidermal dysfunction and ASD. In the murine model, mice with ASD display epidermal dysfunction, accompanied by increased expression levels of proinflammatory cytokines in both the skin and the brain. Children with ASD, which develops in their early lifetime, also exhibit altered epidermal function. Interestingly, improvement in epidermal function alleviates some symptoms of ASD. This line of evidence suggests a pathogenic role of cutaneous dysfunction in ASD. Either an improvement in epidermal function or effective treatment of inflammatory dermatoses can be an alternative approach to the management of ASD. We summarize here the current evidence of the association between the skin and ASD.
Keywords: epidermal permeability barrier, hydration, stratum corneum, autism, inflammation
1. Introduction
Neurological disorders are common and can involve both children and adults with various prevalence, depending on geographic region, age, and gender. For instance, the prevalence of autism spectrum disorder (ASD), also termed autism, is approximately 2.21% in adults (1) and 1.4–2.8% in children aged 8 years in the United States (2, 3). In children, the prevalence of ASD increases with age, with a higher prevalence in boys (4.4% at the age of 10 years) than in girls (1.2% at the age of 10 years) (4). Similarly, a higher portion of adults with ASD are men (69.3% vs. 30.7%) (5). However, the gender differences in prevalence decline after age of 35 years (5). Moreover, a higher prevalence was observed in North America and high-income countries than in other regions and low-income countries (6). In adults, ASD is associated with intellectual, physical, and mental disabilities (5). Children with ASD display delayed mental development in multiple domains, with a negative correlation of developmental levels with disease severity (7). The annual medical costs for adult outpatients with ASD are five times of that for those without ASD ($4,375 vs. $824) (8). Average annual medical costs for children with ASD are nine times for those without ASD ($9,980 vs. $1102) (9). Thus, ASD is common and can negatively impact patients’ lives and economy.
ASD includes non-syndromic and syndromic autism. The latter is mainly caused by chromosomal abnormalities or monogenic alterations (10). Regarding the etiologies of non-syndromic ASD, it is still unclear yet. Although genetic and environmental factors can contribute to the development of ASD (11), evidence also indicates an association of ASD with immune function. For example, the prevalence of allergies and autoimmune diseases is higher in individuals with ASD than in those without ASD in both children and young adults (12–15). Epidemiological studies reveal a higher prevalence of ASD in individuals with inflammatory skin disorders, such as atopic dermatitis and psoriasis (12, 16). A recent study demonstrates epidermal dysfunction, which can provoke cutaneous and systemic inflammation, in children with ASD (17). In this perspective review, we summarize the evidence of a link between the skin and ASD and discuss the implication.
2. Link between dermatoses and ASD
The pathogenic role of inflammation in ASD has been well demonstrated (18, 19). Individuals with ASD display the upregulation of activator protein-1-mediated neuroinflammation and insulin/insulin-like growth factor-1 signaling pathways in the brain (20) although one study showed no significant differences in expression levels of either proinflammatory or anti-inflammatory genes, including IL-1β, in both the gray and white matter of the brain in normal vs. individuals with ASD (21). Moreover, the activation state of astrocytes is increased in both the gray and white matter of prefrontal areas in individuals with ASD, indicating the presence of chronic inflammation in the brain (22). Furthermore, circulating levels of some proinflammatory cytokines, such as IL-1β, IL-6, TNF-α, and IFN-γ, are also higher in individuals with ASD than in the controls (23–25), while circulating levels of anti-inflammatory cytokines, such as IL-10 and IL-1Ra, are decreased in individuals with ASD (26). Although this line of evidence suggests a pathogenic role of inflammation in ASD, the origins of inflammation are still inconclusive. Some studies demonstrate the contribution of inflammation associated with dysbiosis and/or with the increased gut permeability to the pathogenesis of ASD (26–30). Maternal immune activation is also a risk factor for ASD in offspring (31–33). However, a great bulk of evidence indicates a link between cutaneous inflammation to ASD. Moreover, the association of other cutaneous conditions with ASD has also been reported. The evidence of the link between the skin and ASD is summarized in Table 1 (12, 16, 34–67).
Table 1.
Association of autism with cutaneous function.
Cutaneous conditions/subjects | Association with autism spectrum disorder (ASD) | References |
---|---|---|
Psoriasis | ||
3–26 years old; 5,565 cases with autism (1,102 female and 4,563 male patients) and 27,825 controls (5,010 female and 22,815 male patients) | Prevalence of psoriasis is higher in children with ASD than in the controls (0.34% vs. 0.15%; OR = 2.35, 95% CI 1.36–4.08) | (12) |
2–5 years old; 663 cases of ASD (117 female and 546 male patients) and 915 controls (419 female and 496 male patients) | 81 cases of ASD (13.42%) with a family history of psoriasis/eczema; 95 controls (10.38%) with a family history of psoriasis/eczema. p = 0.07 | (34) |
Analyses of 708,517 families | Neither paternal nor maternal psoriasis increases the risk of ASD for their offspring | (35) |
1,386,260 children aged 9.7 ± 2.3 years | A family history of psoriasis is not a risk factor for ASD | (36) |
Eczematous dermatitis | ||
42,641 children and adults with AD and 71,699 controls | AD vs. Non-AD: OR = 1.24; 95% CI = 0.94 ~ 1.64; Mil AD: OR = 1.07, 95% CI = 0.66–1.74; Moderate AD: OR = 0.96, 95% CI = 0.33–2.84; Severe AD: OR = 2.54, 95% CI = 1.54–4.21, p = 0.0003 | (37) |
Analysis of data from 186 countries | No correlation between AD and ASD | (38) |
Children with and without AD each had 387,262 cases. AD was diagnosed at the age of <2 years | Children with AD at age < 2 years have higher risk of ASD than that without AD (adjusted HR = 1.09, 95% CI = 1.02–1.17, p < 0.05) | (39) |
18,473 children with AD aged 1 month to 3 years were enrolled and followed up for 3 years. 18,473 children without AD served as controls | Prevalence of ASD is higher in children with AD than the controls (0.99% vs. 0.09%, p < 0.001). (HR = 8.90, 95% CI = 4.98–15.92) | (40) |
8,130 children with AD were enrolled at birth and followed up for 10–13 years. 6,944 children without AD served as controls | Prevalence of ASD is higher in children with AD than in the controls (0.8% vs. 0.2%, p < 0.0001). (HR = 3.4, 95% CI = 1.95–5.93) | (41) |
25,691 children with AD and 22,713 without AD, aged 2–17 years | Prevalence of ASD is higher in children with AD than in the controls (1.9% vs. 0.9%). (aOR = 1.52, 95% CI = 1.29–1.78, p < 0.001) | (42) |
3,911 ASD cases and 38,609 controls aged 2–12 years | Children with ASD have slightly high prevalence of AD than the controls (21.09% vs. 18.85%; aOR = 1.1, 95% CI = 1.01–1.20) | (43) |
79,667 children aged 0–18 years were analyzed | Prevalence of ASD is higher in children with eczema than in the controls (2.19% vs. 0.89%, p < 0.0001). (OR = 2.51, 95% CI = 1.67–3.77) | (44) |
Phone interview of parents of 27,566 children aged 0–5 years | Prevalence of eczema is higher in children with ASD than in the controls (28.4% vs. 15.4%, aOR = 7.17, 95% CI = 2.56–20.04) | (45) |
41,244 children aged 3–17 years | Prevalence of eczema is higher in children with ASD than in the controls (15.6% vs. 10.2%, aOR = 1.7, 95% CI = 1.2–2.5) | (46) |
341 children aged 3–6 years | Children with higher SCQ score (>11) have a higher prevalence of eczema symptoms than those with lower SCQ score (33.3% vs. 10.4%, p < 0.0001) | (47) |
1,596 children with ASD and 6,384 controls | Prevalence of AD is higher in children with ASD than in the controls (17.8% vs. 13.0%, p < 0.001; OR = 1.52, 95% CI = 1.30–1.78) | (48) |
578 children with ASD and 2,312 controls | Children with ASD have a higher prevalence of AD than the controls (17.3% vs. 11.3%, p < 0.001; OR = 1.24, 95% CI 1.04–1.48) | (49) |
324,000 children with ASD and 61,100,000 without ASD, aged 3–17 years | Children with ASD have a higher prevalence of eczema than the controls (14.9% vs. 9.2%; OR = 1.4, 95% CI =1.0–2.1) | (50) |
2,762 cases with ASD-affected siblings and 11,048 controls | Individuals with ASD -affected siblings had higher incidence of AD (9.9% vs. 8.1%, p = 0.003) with relative risk of 1.22 (95% CI 1.09–1.36) | (51) |
45 atopic (AD >55%) and 93 non-atopic children (mean age 6 years) with autism | Children with atopic condition have higher ADOS CSS scores on total scale than those without atopic condition (7.79 ± 1.51 vs. 7.16 ± 1.86, p = 0.039). ADOS CSS mean scores in the RRB symptom domain do not differ significantly between children with vs. without atopic condition (7.42 ± 1.94 vs. 7.45 ± 2.22, p = 0.943) | (16) |
Children aged 3–26 years, including 5,565 children with ASD and 27,825 controls | Prevalence of dermatitis is comparable in children with vs. without ASD (7.3% vs. 6.9%; OR = 1.07, 95% CI = 0.95–1.20) | (12) |
2,580 children were enrolled at birth and followed up for 2 to 18 years | ASD is not associated with AD (adjust relative risk ratio = 1.38, p = 0.121) | (52) |
26 children with ASD and 107 controls | Prevalence of ASD does not differ significantly between children with or without AD (3.8% vs. 5.6%) | (53) |
24,938 children aged <3 years | Children with AD have a higher risk for ASD (aHR = 1.568, 95% CI = 1.109–2.218, p = 0.011) | (54) |
234,170 children aged 2–18 years | Children with eczematous dermatitis have a higher risk for ASD (aHR = 1.4, 95% CI = 1.28–1.54, p < 0.0001) | (55) |
1,386,260 children aged 9.7 ± 2.3 years | A family member with AD increases the risk for ASD (aHR = 1.29, aHR = 1.25–1.33, p < 0.001) | (36) |
Pigmented skin disorders | ||
A 13-year-old boy born with oculocutaneous albinism had symptoms of ASD on growing up | (56) | |
Three families with ASD and oculocutaneous albinism | (57) | |
Two boys with ASD and oculocutaneous albinism | (58) | |
Two siblings with ASD and oculocutaneous albinism | (59) | |
In two families, each has a twin with ASD and hypomelanosis of Ito | (60) | |
Two girls and a boy have both ASD and hypomelanosis of Ito | (61) | |
Prevalence of hyperpigmented skin disorders is higher in children with ASD than in those without ASD (56.8% vs. 32.6%, OR = 3.12, p = 0.0001). Pigmentary mosaicism of hyperpigmented type (OR = 2.76, p = 0.02); Café-au-lait macules (CALMs) (OR = 2.40, p = 0.001) | (62) | |
X-linked ichthyosis | ||
Five boys with X-linked ichthyosis also have ASD | (63) | |
A boy has both X-linked ichthyosis and ASD | (64) | |
3 out of 58 adults and 4 out of 24 children with X-linked ichthyosis have ASD | (65) | |
1% (1/94) of female carriers of genetic mutations associated with X-linked ichthyosis have ASD | (66) | |
A boy with X-linked ichthyosis has ASD | (67) |
OR, odds ratio; aOR, adjusted odds ratio; HR, hazard ratio; aHR, adjusted hazard ratio; ADOS, Autism Diagnostic Observation Schedule; CSS, calibrated severity scores; CSS-SA, subdomains of social affect; CSS-RRB, restricted and repetitive behavior; AD, atopic dermatitis; SCQ, Social Communication Questionnaire.
2.1. Psoriasis
Psoriasis, a chronic inflammatory disorder, is linked to a number of extracutaneous comorbidities, such as cardiovascular diseases, diabetes, and obesity (68, 69). Studies also show a link between psoriasis and ASD. For example, the prevalence of psoriasis in children with ASD is twice as that in children without ASD (0.34% vs. 0.15%, OR = 2.35, 95% CI = 1.36–4.08) (12). Interestingly, a family history of psoriasis is also a risk factor for ASD for offspring (aHR = 1.55, 95% CI = 1.07–2.23, p = 0.019) (36). Although one study did not show the link between ADS and maternal immune conditions, such as psoriasis, in children (70), Croen et al. reported that 13.4% of individuals with ASD have a maternal history of psoriasis (34). The same group conducted another study in 407 cases of ASD and 2095 controls. The results showed that the mothers of 2.7% of children with ASD had psoriasis at the time of pregnancy, while the mothers of 1% of children with ASD had psoriasis in the controls (aOR = 2.7, 95% CI = 1.3–5.8, p = 0.003) (71). This phenomenon is likely due to the inflammation in the brain of offspring, induced by IL-17A, a key cytokine in psoriasis, from the mother because injection of IL-17A into fetal lateral ventricle can induce ASD-like phenotype in mice (72). The link between psoriasis and ASD is further supported by several observations in mice and humans. First, circulating levels of IL-17 are elevated in subjects with either psoriasis or ASD (including murine models) (73–75). Similarly, increased levels of IL-17A have also been demonstrated in the brain of mice with ASD (76). Second, serum IL-17A levels are positively correlated with the severity of ASD in humans (74). The inhibition of IL-17A signaling improves ASD symptoms in a mouse model of ASD (77). Similarly, the treatment of psoriasis with Secukinumab, an IL-17A inhibitor, also alleviates psychological symptoms of ASD in humans (78). Collectively, this line of evidence indicates a link between ASD and psoriasis.
2.2. Eczematous dermatitis
Eczematous dermatitis, another common inflammatory skin condition, exhibits elevated circulating levels of cytokines, including IL-17 (79, 80), which has been linked to the development of ASD (72, 81). Several epidemiological studies demonstrate an association of eczematous dermatitis with ASD. For example, up to 25% of children with ASD had atopic dermatitis (82, 83). Similarly, a study in a large cohort showed that the prevalence of eczema is higher in children with ASD than in the controls (28.4% vs. 15.4%, aOR = 7.17, 95% CI = 2.56–20.04) (45). Similarly, more than 52% of individuals with ASD have allergic manifestations (including atopic dermatitis) (vs. 10% in subjects without ASD, p < 0.001) (84). Interestingly, children with ASD-affected siblings have a higher risk for atopic dermatitis with a relative risk ratio of 1.22 (95% CI = 1.09–1.36) (incidence 9.9% vs. 8.1%, p = 0.003) (51). On the other hand, the prevalence of ASD is higher in children with atopic dermatitis than in the controls in Chinese (0.99% vs. 0.09%, p < 0.001; HR = 8.90, 95% CI = 4.98–15.92) (40). Another study conducted in the US showed that the prevalence of ASD in children with atopic dermatitis was twice of that in children without atopic dermatitis (1.9% vs. 0.9%, aOR = 1.52, 95% CI = 1.29–1.78, p < 0.001) (42). Atopic dermatitis does not only increase the risk for ASD but also increases the severity of ASD. The Autism Diagnostic Observation Schedule Calibrated Severity scores are higher in children with both ASD and atopic dermatitis than in those with ASD alone (p < 0.05) (16). However, some studies did not show differences in the prevalence of ASD between children with vs. without atopic dermatitis (12, 52, 53). The discrepant results in the association of ASD with atopic dermatitis could be due to the severity of atopic dermatitis in the individuals because only children with severe atopic dermatitis are associated with the risk for ASD (OR = 2.54, 95% CI = 1.54–42.1, p = 0.003) (37). But odds ratios of ASD in individuals with mild and moderate atopic dermatitis are 1.07 (95% CI = 0.66–1.74) and 0.96 (95% CI = 0.33–2.84), respectively (37). Additionally, mothers who have atopic eczema at the time of pregnancy increase the risk of ASD for offspring (aOR = 1.8, 95% CI = 1.0–3.4, p = 0.04) (66). Taken together, this line of evidence demonstrates a link between ASD and eczematous dermatitis.
2.3. Other skin disorders
In addition to inflammatory dermatoses, other cutaneous conditions are also associated with ASD. There are several reports of an association between hypomelanotic disorders and ASD (56–61). For example, linear and whorled hypermelanosis complicated with ASD has also been reported (85, 86). Studies showed that up to 60% of individuals with hypomelanotic disorders have ASD [reviewed in (87)]. It has been postulated that vitamin D deficiency contributes to the pathogenesis of ASD in hypomelanotic disorders. This theory could hold true to some extent. Epidemiological studies showed that lower levels of maternal vitamin D increase the risk of ASD for offspring (88) and that children with ASD have lower levels of serum vitamin D (89). Moreover, because of the sunburn concern, individuals with hypomelanotic disorders may try to avoid sun exposure, resulting in a reduction in endogenous production of active vitamin D in the body. Vitamin deficiency has been linked to inflammatory disorders (90). This assumption is also supported by several observations: (a) serum vitamin D levels are negatively correlated with levels of inflammatory markers (C-reactive protein, calprotectin, and fibrinogen) and disease severity in individuals with either Crohn’s disease or ulcerative colitis (91); (b) supplement of vitamin D lowers levels of proinflammatory cytokines in vitro and in vivo (92, 93). However, hyperpigmented skin disorder can also be complicated with ASD. Pinheiro et al. reported that a 5-year-old boy with hyperpigmentation along the lines of Blaschko was complicated with ASD (94). Thus, further studies are needed to elucidate the underlying mechanisms by which pigmented skin disorders are linked to ASD. Other cutaneous conditions, such as alopecia areata and X-linked ichthyosis, can also be complicated with ASD. For instance, the prevalence of alopecia areata in individuals with ASD is higher than in that without alopecia areata (13.61% vs. 10.43%, HR = 1.238, 95% CI = 1.100–1.395) (95). There are also several case reports of ASD complicated with X-linked ichthyosis or microphthalmia with linear skin defects syndrome (63–67, 96). Nevertheless, these multiple lines of evidence indicate a link between skin disorders and ASD.
In addition to skin disorders, stimulation of the skin with deep pressure alleviates physiological responses, including decreased heart rate and skin conductance, in children with ASD (97, 98). However, the deep pressure-induced changes in physiological function are likely attributable to the altered neural function via efferent pathways and sudomotor impulses, resulting from the discomfort caused by deep pressure (97, 99). Moreover, the contact of the skin of the subject can also influence the symptoms of ASD, depending on the sensory responses. For example, hypo-responsiveness, but not hyper-responsiveness, to tactile stimuli is associated with aberrant social and communication (100). Hence, the skin is also associated with ASD in individuals without dermatoses.
3. Association of epidermal dysfunction and ASD
As aforementioned, ASD is associated with a number of skin disorders. Recent studies also demonstrated alterations in epidermal function in ASD. In the murine model of ASD, mice with ASD exhibit dry skin and a remarkable increase in transepidermal water loss rates, an indicator of epidermal permeability barrier function, compared to normal mice (76). Similarly, adult humans with ASD also display elevated transepidermal water loss rates (76). Recently, Wang et al. compared epidermal biophysical properties in 48 control children and 56 children with ASD (17). All participants were without a current or previous history of inflammatory skin disorders. Children with ASD exhibited higher transepidermal water loss rates, lower stratum corneum hydration levels, and elevated skin surface pH (all p < 0.0001 vs. controls), indicating epidermal dysfunction in ASD. Most importantly, the ASD symptom such as the Social Responsiveness Scale was significantly improved following the correction of epidermal functional abnormalities with topical emollient (CURECODE®) twice daily for 2 months (146.40 ± 4.83 vs. 136.8 ± 5.70, t = 2.988, p < 0.01). The autism treatment evaluation checklist and repetitive behaviors scale-revised were also markedly reduced (p = 0.0777 and p = 0.0621, respectively) (101). These results suggest that ASD is also linked to epidermal dysfunction.
4. Perspectives
ASD is a common neurological disorder with a worldwide prevalence of as high as 4.36% (102). The etiologies of ASD have been widely speculated. Evidence suggests that ASD can be attributed to genetic, epigenetic, and environmental factors in addition to microbiome (10, 103–105). Indeed, a family history of ASD increases the odds of ASD in their children by 7.4–16.2 times (106). Somatic variants account for 3–5% of ASD (107, 108). If one has ASD, the other one is more likely to have it in monozygotic twins (109). Epigenetic modifications, such as DNA methylation and histone modification, also contribute to the development of ASD (105). Moreover, several studies demonstrate the role of gut microbiota in the pathogenesis of ASD (110, 111). Children with ASD have a high incidence of gastrointestinal disorders, such as constipation and diarrhea (112). Children with constipation have a higher risk of ASD (adjusted hazard ratio = 1.431, 95% CI = 1.083–1.891) (54). Both gut microbiota and their metabolic products are altered in humans and animals with ASD (113–115). In comparison to the non-ASD controls, children with ASD have higher fecal levels of Caloramator, Sarcina, and Clostridium genera and lower levels of Eubacteriaceae (116). The pathogenic role of gut microbiota in ASD is further supported by the evidence that oral probiotics during pregnancy prevent both the development of ASD symptoms and the increases in IL-6 and IL-17a levels in the brain of offspring induced by maternal immune activation (117). Similarly, orally given human commensal bacteroides fragilis alleviates ASD symptoms, improves gut permeability, and alters microbial composition in a mouse model of ASD induced by maternal immune activation (118). Apparently, the pathogenic role of microbiota in ASD is mediated by inflammation. The structural components of the bacteria can induce the production of proinflammatory cytokines, including IL-1β, IL-6, and TNF-α (110, 119). Individuals with ASD exhibit high intestinal permeability, resulting in an increased antigenic load from the gastrointestinal tract (113). Similarly, the brain–blood barrier is also compromised in individuals with ASD (120). Cytokines, such as IL-1β, IL-6, IFN-γ, and TNF-α, released from the intestine can easily penetrate into the circulation and cross the blood–brain barrier into the brain, consequently leading to the development of ASD (110). In support of the inflammation theory, individuals with ASD display higher levels of proinflammatory cytokines in both circulation and the brain (74, 76, 117, 121), while circulating levels of anti-inflammatory cytokines, such as IL-10 and IL-1Ra, are lower in individuals with ASD vs. normal controls (122). Accordingly, an anti-inflammation regimen improves symptoms of ASD (123). Thus, inflammation plays a central role in the development of ASD.
Consistent with the notion of the central role of inflammation in ASD, inflammatory dermatoses, such as psoriasis and eczematous dermatitis, predispose to the development of ASD. First, the development of ASD occurs approximately 6 months following the first appearance of allergic disorders in children (55). Second, in the murine model of ASD, increased cytokine levels in the brain are later than those in the skin (76). Third, the treatment of psoriasis with Secukinumab improves the symptoms of ASD (78). Coupling with the evidence of a positive correlation of the severity of ASD symptoms with the severity of atopic dermatitis, cytokines of cutaneous origin can also contribute to the development of ASD. However, a maximum of 28% of individuals with ASD have atopic dermatitis (45). Not all individuals with ASD have gastrointestinal disorders. Then, the question is where the inflammation is in individuals without either gastrointestinal disorders or inflammatory skin diseases. A bulk of evidence suggests a possible contribution of epidermal dysfunction to inflammation in both circulation and the brain. First, children with ASD, but without allergic disorders nor inflammatory dermatoses, display alterations in epidermal biophysical properties, including elevations in transepidermal water loss rates and skin surface pH and reduction in stratum corneum hydration levels (17). Second, elevation in transepidermal water loss rates increases levels of proinflammatory cytokines in both circulation and the skin (124). Third, reduction in stratum corneum hydration levels increases cutaneous inflammation (125–127), while circulating levels of proinflammatory cytokines are negatively correlated with stratum corneum hydration levels in humans without apparent inflammatory cutaneous inflammation (128). Because of the huge surface area of the skin (2 m2 for adult males and 1.7 m2 for adult females) (129), even mild cutaneous inflammation induced by epidermal dysfunction can increase proinflammatory cytokines in circulation. Elevated circulating levels of proinflammatory cytokines downregulate expression levels of a tight junction protein (occludin 1), as well as vascular cell adhesion molecule 1 in the endothelial cells of the brain, leading to an increase in blood–brain permeability, subsequently resulting in inflammation in the brain (130). Finally, improvement in epidermal function lowers circulating levels of proinflammatory cytokines in both humans and mice (124, 131) and alleviates some symptoms of ASD in children without any inflammatory dermatoses in addition to mitigation of other psychological symptoms such as cognitive impairment in adults (101, 132). Hence, this pile of evidence indicates that the development of ASD can be attributable, at least in part, to epidermal dysfunction. Because of the regulatory role of epidermal function in cutaneous inflammation, improvement in epidermal function can benefit ASD.
5. Conclusion
ASD is common in both adults and children. Although therapeutic regimens, such as medication and behavior management, are available, there are still challenges in clinical practice. Medicines, such as risperidone and aripiprazole, can cause some side effects, including somnolence, extra-pyramidal symptoms, hyperprolactinemia, body weight gain, headache, and urinary incontinence. (133, 134). Moreover, either medication or behavior management can only improve symptoms without solving the fundamental problem, inflammation, a key contributor to the pathogenesis of ASD. However, recent studies showed that an improvement in epidermal function with topical emollients can lower cytokine levels in both the skin and circulation of mice and humans (124, 131). Similarly, topical emollients can both improve and prevent the development of inflammatory skin disorders, including atopic dermatitis and psoriasis (135–139), which both are associated with ASD, as mentioned above. Taken together with the evidence that topical emollients improve symptoms of ASD and mitigate the progression of cognitive impairment, which both are linked to inflammation, either improvement in epidermal function with emollients, especially in individuals with epidermal dysfunction or effective treatments of inflammatory dermatoses can be an alternative approach in the management of ASD. However, this speculation needs to be validated in appropriate clinical trials.
Data availability statement
The original contributions presented in the study are included in the article/supplementary material, further inquiries can be directed to the corresponding authors.
Author contributions
M-QM: Conceptualization, Writing – original draft, Writing – review & editing. SY: Data curation, Formal analysis, Investigation, Writing – original draft. TM: Writing – review & editing. GZ: Conceptualization, Data curation, Formal analysis, Writing – review & editing. TZ: Writing – review & editing, Conceptualization, Data curation.
Funding Statement
The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This study was partially supported with the resources from the Research Service, Department of Veterans Affairs Medical Center San Francisco, CA, United States.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
- 1.Dietz PM, Rose CE, McArthur D, Maenner M. National and state estimates of adults with autism Spectrum disorder. J Autism Dev Disord. (2020) 50:4258–66. doi: 10.1007/s10803-020-04494-4 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Christensen DL, Braun KVN, Baio J, Bilder D, Charles J, Constantino JN, et al. Prevalence and characteristics of autism Spectrum disorder among children aged 8 years - autism and developmental disabilities monitoring network, 11 sites, United States, 2012. MMWR Surveill Summ. (2018) 65:1–23. doi: 10.15585/mmwr.ss6513a1, PMID: [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Autism Prevalence Higher, According to Data from 11 ADDM Communities . Available at: https://www.cdc.gov/media/releases/2023/p0323-autism.html (Accessed May 2, 2023).
- 4.Rydzewska E, Hughes-McCormack LA, Gillberg C, Henderson A, MacIntyre C, Rintoul J, et al. Age at identification, prevalence and general health of children with autism: observational study of a whole country population. BMJ Open. (2019) 9:e025904. doi: 10.1136/bmjopen-2018-025904, PMID: [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Rydzewska E, Hughes-McCormack LA, Gillberg C, Henderson A, MacIntyre C, Rintoul J, et al. Prevalence of long-term health conditions in adults with autism: observational study of a whole country population. BMJ Open. (2018) 8:e023945. doi: 10.1136/bmjopen-2018-023945, PMID: [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Talantseva OI, Romanova RS, Shurdova EM, Dolgorukova TA, Sologub PS, Titova OS, et al. The global prevalence of autism spectrum disorder: a three-level meta-analysis. Front Psych. (2023) 14:1071181. doi: 10.3389/fpsyt.2023.1071181, PMID: [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Li HH, Wang CX, Feng JY, Wang B, Li CL, Jia FY. A developmental profile of children with autism Spectrum disorder in China using the Griffiths mental development scales. Front Psychol. (2020) 11:570923. doi: 10.3389/fpsyg.2020.570923, PMID: [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Vohra R, Madhavan S, Sambamoorthi U. Comorbidity prevalence, healthcare utilization, and expenditures of Medicaid enrolled adults with autism spectrum disorders. Autism. (2017) 21:995–1009. doi: 10.1177/1362361316665222, PMID: [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Mandell DS, Cao J, Ittenbach R, Pinto-Martin J. Medicaid expenditures for children with autistic spectrum disorders: 1994 to 1999. J Autism Dev Disord. (2006) 36:475–85. doi: 10.1007/s10803-006-0088-z, PMID: [DOI] [PubMed] [Google Scholar]
- 10.Sauer AK, Stanton JE, Hans S, Grabrucker AM. Autism Spectrum disorders: etiology and pathology In: Grabrucker AM, editor. Autism Spectrum disorders [internet]. Brisbane: Exon Publications; (2021) Available at: https://www.ncbi.nlm.nih.gov/books/NBK573613/ [PubMed] [Google Scholar]
- 11.Pendergrass S, Girirajan S, Selleck S. Uncovering the etiology of autism spectrum disorders: genomics, bioinformatics, environment, data collection and exploration, and future possibilities. Pac Symp Biocomput. (2014) 2014:422–6. [PMC free article] [PubMed] [Google Scholar]
- 12.Zerbo O, Leong A, Barcellos L, Bernal P, Fireman B, Croen LA. Immune mediated conditions in autism spectrum disorders. Brain Behav Immun. (2015) 46:232–6. doi: 10.1016/j.bbi.2015.02.001 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Lyall K, Van de Water J, Ashwood P, Hertz-Picciotto I. Asthma and allergies in children with autism Spectrum disorders: results from the CHARGE study. Autism Res. (2015) 8:567–74. doi: 10.1002/aur.1471 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14.Tan Y, Thomas S, Lee BK. Parent-reported prevalence of food allergies in children with autism spectrum disorder: national health interview survey, 2011-2015. Autism Res. (2019) 12:802–5. doi: 10.1002/aur.2106, PMID: [DOI] [PubMed] [Google Scholar]
- 15.Xu G, Snetselaar LG, Jing J, Liu B, Strathearn L, Bao W. Association of Food Allergy and Other Allergic Conditions with Autism Spectrum Disorder in children. JAMA Netw Open. (2018) 1:e180279. doi: 10.1001/jamanetworkopen.2018.0279 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16.Jameson C, Boulton KA, Silove N, Guastella AJ. Eczema and related atopic diseases are associated with increased symptom severity in children with autism spectrum disorder. Transl Psychiatry. (2022) 12:415. doi: 10.1038/s41398-022-02185-5 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17.Wang B, Li YD, Wang ZY, Zhao JQ, Zhang GQ, Man MQ. Alterations in epidermal biophysical properties in autistic children. Skin Pharmacol Physiol. (2023) 36:160–4. doi: 10.1159/000530140, PMID: [DOI] [PubMed] [Google Scholar]
- 18.Eissa N, Sadeq A, Sasse A, Sadek B. Role of neuroinflammation in autism spectrum disorder and the emergence of brain histaminergic system. Lessons Also for BPSD? Front Pharmacol. (2020) 11:886. doi: 10.3389/fphar.2020.00886 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19.Masi A, Glozier N, Dale R, Guastella AJ. The immune system, cytokines, and biomarkers in autism Spectrum disorder. Neurosci Bull. (2017) 33:194–204. doi: 10.1007/s12264-017-0103-8, PMID: [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20.Cristiano C, Lama A, Lembo F, Mollica MP, Calignano A, Mattace RG. Interplay between peripheral and central inflammation in autism Spectrum disorders: possible nutritional and therapeutic strategies. Front Physiol. (2018) 9:184. doi: 10.3389/fphys.2018.00184, PMID: [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21.Zhang P, Omanska A, Ander BP, Gandal MJ, Stamova B, Schumann CM. Neuron-specific transcriptomic signatures indicate neuroinflammation and altered neuronal activity in ASD temporal cortex. Proc Natl Acad Sci U S A. (2023) 120:e2206758120. doi: 10.1073/pnas.2206758120 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22.Sciara AN, Beasley B, Crawford JD, Anderson EP, Carrasco T, Zheng S, et al. Neuroinflammatory gene expression alterations in anterior cingulate cortical white and gray matter of males with autism Spectrum disorder. Autism Res. (2020) 13:870–84. doi: 10.1002/aur.2284 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23.Vakilzadeh G, Falcone C, Dufour B, Hong T, Noctor SC, Martínez-Cerdeño V. Decreased number and increased activation state of astrocytes in gray and white matter of the prefrontal cortex in autism. Cereb Cortex. (2022) 32:4902–12. doi: 10.1093/cercor/bhab523, PMID: [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24.Saghazadeh A, Ataeinia B, Keynejad K, Abdolalizadeh A, Hirbod-Mobarakeh A, Rezaei N. A meta-analysis of pro-inflammatory cytokines in autism spectrum disorders: effects of age, gender, and latitude. J Psychiatr Res. (2019) 115:90–102. doi: 10.1016/j.jpsychires.2019.05.019, PMID: [DOI] [PubMed] [Google Scholar]
- 25.El-Ansary A, Al-Ayadhi L. Neuroinflammation in autism spectrum disorders. J Neuroinflammation. (2012) 9:265. doi: 10.1186/1742-2094-9-265 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26.Cao X, Liu K, Liu J, Liu YW, Xu L, Wang H, et al. Dysbiotic gut microbiota and dysregulation of cytokine profile in children and teens with autism Spectrum disorder. Front Neurosci. (2021) 15:635925. doi: 10.3389/fnins.2021.635925, PMID: [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27.Chen Y, Fang H, Li C, Wu G, Xu T, Yang X, et al. Gut Bacteria shared by children and their mothers associate with developmental level and social deficits in autism Spectrum disorder. mSphere. (2020) 5:e01044–20. doi: 10.1128/mSphere.01044-20 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28.Zou R, Xu F, Wang Y, Duan M, Guo M, Zhang Q, et al. Changes in the gut microbiota of children with autism Spectrum disorder. Autism Res. (2020) 13:1614–25. doi: 10.1002/aur.2358 [DOI] [PubMed] [Google Scholar]
- 29.Ding X, Xu Y, Zhang X, Zhang L, Duan G, Song C, et al. Gut microbiota changes in patients with autism spectrum disorders. J Psychiatr Res. (2020) 129:149–59. doi: 10.1016/j.jpsychires.2020.06.032 [DOI] [PubMed] [Google Scholar]
- 30.Teskey G, Anagnostou E, Mankad D, Smile S, Roberts W, Brian J, et al. Intestinal permeability correlates with behavioural severity in very young children with ASD: a preliminary study. J Neuroimmunol. (2021) 357:577607. doi: 10.1016/j.jneuroim.2021.577607, PMID: [DOI] [PubMed] [Google Scholar]
- 31.Parker-Athill EC, Tan J. Maternal immune activation and autism spectrum disorder: interleukin-6 signaling as a key mechanistic pathway. Neurosignals. (2010) 18:113–28. doi: 10.1159/000319828, PMID: [DOI] [PMC free article] [PubMed] [Google Scholar]
- 32.Yasumatsu K, Nagao JI, Arita-Morioka KI, Narita Y, Tasaki S, Toyoda K, et al. Bacterial-induced maternal interleukin-17A pathway promotes autistic-like behaviors in mouse offspring. Exp Anim. (2020) 69:250–60. doi: 10.1538/expanim.19-0156, PMID: [DOI] [PMC free article] [PubMed] [Google Scholar]
- 33.Dutra ML, Dias P, Freiberger V, Ventura L, Comim CM, Martins DF, et al. Maternal immune activation induces autism-like behavior and reduces brain-derived neurotrophic factor levels in the hippocampus and offspring cortex of C57BL/6 mice. Neurosci Lett. (2023) 793:136974. doi: 10.1016/j.neulet.2022.136974, PMID: [DOI] [PubMed] [Google Scholar]
- 34.Croen LA, Qian Y, Ashwood P, Daniels JL, Fallin D, Schendel D, et al. Family history of immune conditions and autism spectrum and developmental disorders: findings from the study to explore early development. Autism Res. (2019) 12:123–35. doi: 10.1002/aur.1979, PMID: [DOI] [PMC free article] [PubMed] [Google Scholar]
- 35.Lee H, Hsu JW, Tsai SJ, Huang KL, Bai YM, Su TP, et al. Risk of attention deficit hyperactivity and autism spectrum disorders among the children of parents with autoimmune diseases: a nationwide birth cohort study. Eur Child Adolesc Psychiatry. (2023) 32:283–91. doi: 10.1007/s00787-021-01860-0 [DOI] [PubMed] [Google Scholar]
- 36.Li DJ, Tsai CS, Hsiao RC, Chen YL, Yen CF. Associations between allergic and autoimmune diseases with autism Spectrum disorder and attention-deficit/hyperactivity disorder within families: a population-based cohort study. Int J Environ Res Public Health. (2022) 19:4503. doi: 10.3390/ijerph19084503 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 37.Ahn HJ, Shin MK, Seo JK, Jeong SJ, Cho AR, Choi SH, et al. Cross-sectional study of psychiatric comorbidities in patients with atopic dermatitis and nonatopic eczema, urticaria, and psoriasis. Neuropsychiatr Dis Treat. (2019) 15:1469–78. doi: 10.2147/NDT.S191509, PMID: [DOI] [PMC free article] [PubMed] [Google Scholar]
- 38.Tonacci A, Pioggia G, Gangemi S. Autism spectrum disorders and atopic dermatitis: a new perspective from country-based prevalence data. Clin Mol Allergy. (2021) 19:27. doi: 10.1186/s12948-021-00166-5, PMID: [DOI] [PMC free article] [PubMed] [Google Scholar]
- 39.Liao TC, Lien YT, Wang S, Huang SL, Chen CY. Comorbidity of atopic disorders with autism Spectrum disorder and attention deficit/hyperactivity disorder. J Pediatr. (2016) 171:248–55. doi: 10.1016/j.jpeds.2015.12.063, PMID: [DOI] [PubMed] [Google Scholar]
- 40.Lee CY, Chen MH, Jeng MJ, Hsu JW, Tsai SJ, Bai YM, et al. Longitudinal association between early atopic dermatitis and subsequent attention-deficit or autistic disorder: a population-based case-control study. Medicine (Baltimore). (2016) 95:e5005. doi: 10.1097/MD.0000000000005005 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 41.Chen MH, Su TP, Chen YS, Hsu JW, Huang KL, Chang WH, et al. Is atopy in early childhood a risk factor for ADHD and ASD? A longitudinal study. J Psychosom Res. (2014) 77:316–21. doi: 10.1016/j.jpsychores.2014.06.006, PMID: [DOI] [PubMed] [Google Scholar]
- 42.Hou A, Silverberg JI. Predictors and age-dependent pattern of psychologic problems in childhood atopic dermatitis. Pediatr Dermatol. (2021) 38:606–12. doi: 10.1111/pde.14588, PMID: [DOI] [PubMed] [Google Scholar]
- 43.Alexeeff SE, Yau V, Qian Y, Davignon M, Lynch F, Crawford P, et al. Medical conditions in the first years of life associated with future diagnosis of ASD in children. J Autism Dev Disord. (2017) 47:2067–79. doi: 10.1007/s10803-017-3130-4, PMID: [DOI] [PMC free article] [PubMed] [Google Scholar]
- 44.Yaghmaie P, Koudelka CW, Simpson EL. Mental health comorbidity in patients with atopic dermatitis. J Allergy Clin Immunol. (2013) 131:428–33. doi: 10.1016/j.jaci.2012.10.041, PMID: [DOI] [PMC free article] [PubMed] [Google Scholar]
- 45.Garg N, Silverberg JI. Association between childhood allergic disease, psychological comorbidity, and injury requiring medical attention. Ann Allergy Asthma Immunol. (2014) 112:525–32. doi: 10.1016/j.anai.2014.03.006, PMID: [DOI] [PubMed] [Google Scholar]
- 46.Schieve LA, Gonzalez V, Boulet SL, Visser SN, Rice CE, Van Naarden BK, et al. Concurrent medical conditions and health care use and needs among children with learning and behavioral developmental disabilities, National Health Interview Survey, 2006-2010. Res Dev Disabil. (2012) 33:467–76. doi: 10.1016/j.ridd.2011.10.008, PMID: [DOI] [PubMed] [Google Scholar]
- 47.Hori D, Tsujiguchi H, Kambayashi Y, Hamagishi T, Kitaoka M, Mitoma J, et al. The Association of Autism Spectrum Disorders and Symptoms of asthma, allergic Rhinoconjunctivitis and eczema among Japanese children aged 3-6 years. Health. (2017) 9:1235–50. doi: 10.4236/health.2017.98089 [DOI] [Google Scholar]
- 48.Chen MH, Su T, Chen Y, Hsu J, Huang K, Chang W, et al. Comorbidity of allergic and autoimmune diseases in patients with autism spectrum disorder: a nationwide population-based study. Res Autism Spectr Disord. (2013) 7:205–12. doi: 10.1016/j.rasd.2012.08.008 [DOI] [Google Scholar]
- 49.Lin TY, Lin PY, Su TP, Chen YS, Hsu JW, Huang KL, et al. Autistic spectrum disorder, attention deficit hyperactivity disorder, and allergy: is there a link? A nationwide study. Res Autism Spectr Disord. (2014) 8:1333–8. doi: 10.1016/j.rasd.2014.07.009 [DOI] [Google Scholar]
- 50.Gurney JG, McPheeters ML, Davis MM. Parental report of health conditions and health care use among children with and without autism: National Survey of Children's health. Arch Pediatr Adolesc Med. (2006) 160:825–30. doi: 10.1001/archpedi.160.8.825 [DOI] [PubMed] [Google Scholar]
- 51.Dai YX, Tai YH, Chang YT, Chen TJ, Chen MH. Increased risk of atopic diseases in the siblings of patients with autism Spectrum disorder: a Nationwide population-based cohort study. J Autism Dev Disord. (2019) 49:4626–33. doi: 10.1007/s10803-019-04184-w, PMID: [DOI] [PubMed] [Google Scholar]
- 52.Qu X, Lee LC, Ladd-Acosta C, Hong X, Ji Y, Kalb LG, et al. Association between atopic diseases and neurodevelopmental disabilities in a longitudinal birth cohort. Autism Res. (2022) 15:740–50. doi: 10.1002/aur.2680, PMID: [DOI] [PMC free article] [PubMed] [Google Scholar]
- 53.Jyonouchi H, Geng L, Cushing-Ruby A, Quraishi H. Impact of innate immunity in a subset of children with autism spectrum disorders: a case control study. J Neuroinflammation. (2008) 5:52. doi: 10.1186/1742-2094-5-52, PMID: [DOI] [PMC free article] [PubMed] [Google Scholar]
- 54.Lee YF, Wu MC, Ma KS, Huang JY, Wei JC. Association of early childhood constipation with the risk of autism spectrum disorder in Taiwan: real-world evidence from a nationwide population-based cohort study. Front Psych. (2023) 14:1116239. doi: 10.3389/fpsyt.2023.1116239, PMID: [DOI] [PMC free article] [PubMed] [Google Scholar]
- 55.Nemet S, Asher I, Yoles I, Baevsky T, Sthoeger Z. Early childhood allergy linked with development of attention deficit hyperactivity disorder and autism spectrum disorder. Pediatr Allergy Immunol. (2022) 33:10.1111/pai.13819. doi: 10.1111/pai.13819 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 56.Bakare MO, Ikegwuonu NN. Childhood autism in a 13 year old boy with oculocutaneous albinism: a case report. J Med Case Rep. (2008) 2:56. doi: 10.1186/1752-1947-2-56, PMID: [DOI] [PMC free article] [PubMed] [Google Scholar]
- 57.Delong R. GABA(a) receptor alpha5 subunit as a candidate gene for autism and bipolar disorder: a proposed endophenotype with parent-of-origin and gain-of-function features, with or without oculocutaneous albinism. Autism. (2007) 11:135–47. doi: 10.1177/1362361307075705, PMID: [DOI] [PubMed] [Google Scholar]
- 58.Rogawski MA, Funderburk SJ, Cederbaum SD. Oculocutaneous albinism and mental disorder. A report of two autistic boys. Hum Hered. (1978) 28:81–5. doi: 10.1159/000152946 [DOI] [PubMed] [Google Scholar]
- 59.Ünsel BG. Case report: diagnosis and treatment of attention deficit hyperactivity disorder and autism spectrum disorder in patients diagnosed with oculocutaneous albinism. Neurocase. (2020) 26:360–3. doi: 10.1080/13554794.2020.1853174, PMID: [DOI] [PubMed] [Google Scholar]
- 60.Zappella M. Autism and hypomelanosis of Ito in twins. Dev Med Child Neurol. (1993) 35:826–32. doi: 10.1111/j.1469-8749.1993.tb11734.x, PMID: [DOI] [PubMed] [Google Scholar]
- 61.Akefeldt A, Gillberg C. Hypomelanosis of Ito in three cases with autism and autistic-like conditions. Dev Med Child Neurol. (1991) 33:737–43. doi: 10.1111/j.1469-8749.1991.tb14953.x, PMID: [DOI] [PubMed] [Google Scholar]
- 62.Varala S, George R, Mathew L, Russell P, Koshy B, Oommen SP, et al. The diagnostic value of congenital and nevoid cutaneous lesions associated with autism Spectrum disorders in Indian children- a case-control study. Indian Dermatol Online J. (2021) 12:84–9. doi: 10.4103/idoj.IDOJ_275_20, PMID: [DOI] [PMC free article] [PubMed] [Google Scholar]
- 63.Kent L, Emerton J, Bhadravathi V, Weisblatt E, Pasco G, Willatt LR, et al. X-linked ichthyosis (steroid sulfatase deficiency) is associated with increased risk of attention deficit hyperactivity disorder, autism and social communication deficits. J Med Genet. (2008) 45:519–24. doi: 10.1136/jmg.2008.057729, PMID: [DOI] [PubMed] [Google Scholar]
- 64.Baek WS, Aypar U. Neurological manifestations of X-linked ichthyosis: case report and review of the literature. Case Rep Genet. (2017) 2017:9086408. doi: 10.1155/2017/9086408 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 65.Chatterjee S, Humby T, Davies W. Behavioural and psychiatric phenotypes in men and boys with X-linked ichthyosis: evidence from a worldwide online survey. PLoS One. (2016) 11:e0164417. doi: 10.1371/journal.pone.0164417, PMID: [DOI] [PMC free article] [PubMed] [Google Scholar]
- 66.Cavenagh A, Chatterjee S, Davies W. Behavioural and psychiatric phenotypes in female carriers of genetic mutations associated with X-linked ichthyosis. PLoS One. (2019) 14:e0212330. doi: 10.1371/journal.pone.0212330 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 67.Malik A, Amer AB, Salama M, Haddad B, Alrifai MT, Balwi MA, et al. X-linked ichthyosis associated with psychosis and behavioral abnormalities: a case report. J Med Case Rep. (2017) 11:267. doi: 10.1186/s13256-017-1420-2, PMID: [DOI] [PMC free article] [PubMed] [Google Scholar]
- 68.Shapiro J, Cohen AD, David M, Hodak E, Chodik G, Viner A, et al. The association between psoriasis, diabetes mellitus, and atherosclerosis in Israel: a case-control study. J Am Acad Dermatol. (2007) 56:629–34. doi: 10.1016/j.jaad.2006.09.017, PMID: [DOI] [PubMed] [Google Scholar]
- 69.Singh SK, Tripathi R. Evaluation of the Association of Metabolic Syndrome with psoriasis and its severity: a cross-sectional study. Indian J Dermatol. (2020) 65:243–4. doi: 10.4103/ijd.IJD_541_17, PMID: [DOI] [PMC free article] [PubMed] [Google Scholar]
- 70.Lyall K, Ashwood P, Van de Water J, Hertz-Picciotto I. Maternal immune-mediated conditions, autism spectrum disorders, and developmental delay. J Autism Dev Disord. (2014) 44:1546–55. doi: 10.1007/s10803-013-2017-2, PMID: [DOI] [PMC free article] [PubMed] [Google Scholar]
- 71.Croen LA, Grether JK, Yoshida CK, Odouli R, Van de Water J. Maternal autoimmune diseases, asthma and allergies, and childhood autism spectrum disorders: a case-control study. Arch Pediatr Adolesc Med. (2005) 159:151–7. doi: 10.1001/archpedi.159.2.151 [DOI] [PubMed] [Google Scholar]
- 72.Fujitani M, Miyajima H, Otani Y, Liu X. Maternal and adult interleukin-17A exposure and autism Spectrum disorder. Front Psych. (2022) 13:836181. doi: 10.3389/fpsyt.2022.836181 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 73.Michalak-Stoma A, Bartosińska J, Kowal M, Raczkiewicz D, Krasowska D, Chodorowska G. IL-17A in the psoriatic Patients' serum and plaque scales as potential marker of the diseases severity and obesity. Mediat Inflamm. (2020) 2020:1–9. doi: 10.1155/2020/7420823 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 74.Al-Ayadhi LY, Mostafa GA. Elevated serum levels of interleukin-17A in children with autism. J Neuroinflammation. (2012) 9:158. doi: 10.1186/1742-2094-9-158 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 75.Thawley AJ, Veneziani LP, Rabelo-da-Ponte FD, Riederer I, Mendes-da-Cruz DA, Bambini-Junior V. Aberrant IL-17 levels in rodent models of autism Spectrum disorder: a systematic review. Front Immunol. (2022) 13:874064. doi: 10.3389/fimmu.2022.874064 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 76.Shin KO, Crumrine DA, Kim S, Lee Y, Kim B, Abuabara K, et al. Phenotypic overlap between atopic dermatitis and autism. BMC Neurosci. (2021) 22:43. doi: 10.1186/s12868-021-00645-0, PMID: [DOI] [PMC free article] [PubMed] [Google Scholar]
- 77.Nadeem A, Ahmad SF, Al-Harbi NO, Attia SM, Bakheet SA, Ibrahim KE, et al. Nrf2 activator, sulforaphane ameliorates autism-like symptoms through suppression of Th17 related signaling and rectification of oxidant-antioxidant imbalance in periphery and brain of BTBR T+tf/J mice. Behav Brain Res. (2019) 364:213–24. doi: 10.1016/j.bbr.2019.02.031, PMID: [DOI] [PubMed] [Google Scholar]
- 78.Bernardini N, Skroza N, Marraffa F, Prevete E, Mambrin A, Proietti I, et al. A case of twins affected by psoriasis, psoriatic arthritis and autism: five years of efficacious and safe treatment with Secukinumab. Dermatol Ther. (2022) 35:e15533. doi: 10.1111/dth.15533, PMID: [DOI] [PMC free article] [PubMed] [Google Scholar]
- 79.Klonowska J, Gleń J, Nowicki RJ, Trzeciak M. New cytokines in the pathogenesis of atopic dermatitis-new therapeutic targets. Int J Mol Sci. (2018) 19:3086. doi: 10.3390/ijms19103086, PMID: [DOI] [PMC free article] [PubMed] [Google Scholar]
- 80.Ruiz de Morales JMG, Puig L, Daudén E, Cañete JD, Pablos JL, Martín AO, et al. Critical role of interleukin (IL)-17 in inflammatory and immune disorders: an updated review of the evidence focusing in controversies. Autoimmun Rev. (2020) 19:102429. doi: 10.1016/j.autrev.2019.102429 [DOI] [PubMed] [Google Scholar]
- 81.Wong H, Hoeffer C. Maternal IL-17A in autism. Exp Neurol. (2018) 299:228–40. doi: 10.1016/j.expneurol.2017.04.010, PMID: [DOI] [PMC free article] [PubMed] [Google Scholar]
- 82.Mostafa GA, Al Shehab A, Fouad NR. Frequency of CD4+CD25high regulatory T cells in the peripheral blood of Egyptian children with autism. J Child Neurol. (2010) 25:328–35. doi: 10.1177/0883073809339393, PMID: [DOI] [PubMed] [Google Scholar]
- 83.Mostafa GA, Al-Ayadhi LY. The possible relationship between allergic manifestations and elevated serum levels of brain specific auto-antibodies in autistic children. J Neuroimmunol. (2013) 261:77–81. doi: 10.1016/j.jneuroim.2013.04.003, PMID: [DOI] [PubMed] [Google Scholar]
- 84.Mostafa GA, Hamza RT, El-Shahawi HH. Allergic manifestations in autistic children: relation to disease severity. J Pediatr Neurol. (2015) 6:115–23. doi: 10.1055/s-0035-1557446 [DOI] [Google Scholar]
- 85.Di Lernia V. Linear and whorled hypermelanosis. Pediatr Dermatol. (2007) 24:205–10. doi: 10.1111/j.1525-1470.2007.00387.x [DOI] [PubMed] [Google Scholar]
- 86.Nehal KS, PeBenito R, Orlow SJ. Analysis of 54 cases of hypopigmentation and hyperpigmentation along the lines of Blaschko. Arch Dermatol. (1996) 132:1167–70. doi: 10.1001/archderm.1996.03890340027005, PMID: [DOI] [PubMed] [Google Scholar]
- 87.Bakare MO, Munir KM, Kinney DK. Associations of hypomelanotic skin disorders with autism: Do they reflect the effects of genetic mutations and epigenetic factors on vitamin-D metabolism in individuals at risk for autism? Hypothesis (Macon). (2011) 9:e2. doi: 10.5779/hypothesis.v9i1.200, PMID: [DOI] [PMC free article] [PubMed] [Google Scholar]
- 88.Grant WB, Soles CM. Epidemiologic evidence supporting the role of maternal vitamin D deficiency as a risk factor for the development of infantile autism. Dermatoendocrinol. (2009) 1:223–8. doi: 10.4161/derm.1.4.9500, PMID: [DOI] [PMC free article] [PubMed] [Google Scholar]
- 89.Meguid NA, Hashish AF, Anwar M, Sidhom G. Reduced serum levels of 25-hydroxy and 1,25-dihydroxy vitamin D in Egyptian children with autism. J Altern Complement Med. (2010) 16:641–5. doi: 10.1089/acm.2009.0349, PMID: [DOI] [PubMed] [Google Scholar]
- 90.Li Y, Si H, Ma Y, Li S, Gao L, Liu K, et al. Vitamin D3 affects the gut microbiota in an LPS-stimulated systemic inflammation mouse model. Microbes Infect. (2023) 105180:105180. doi: 10.1016/j.micinf.2023.105180 [DOI] [PubMed] [Google Scholar]
- 91.López-Muñoz P, Beltrán B, Sáez-González E, Alba A, Nos P, Iborra M. Influence of vitamin D deficiency on inflammatory markers and clinical disease activity in IBD patients. Nutrients. (2019) 11:1059. doi: 10.3390/nu11051059, PMID: [DOI] [PMC free article] [PubMed] [Google Scholar]
- 92.Calton EK, Keane KN, Newsholme P, Soares MJ. The impact of vitamin D levels on inflammatory status: a systematic review of immune cell studies. PLoS One. (2015) 10:e0141770. doi: 10.1371/journal.pone.0141770, PMID: [DOI] [PMC free article] [PubMed] [Google Scholar]
- 93.Mousa A, Naderpoor N, Teede H, Scragg R, de Courten B. Vitamin D supplementation for improvement of chronic low-grade inflammation in patients with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. Nutr Rev. (2018) 76:380–94. doi: 10.1093/nutrit/nux077, PMID: [DOI] [PubMed] [Google Scholar]
- 94.Pinheiro A, Mathew MC, Thomas M, Jacob M, Srivastava VM, Cherian R, et al. The clinical profile of children in India with pigmentary anomalies along the lines of Blaschko and central nervous system manifestations. Pediatr Dermatol. (2007) 24:11–7. doi: 10.1111/j.1525-1470.2007.00325.x, PMID: [DOI] [PubMed] [Google Scholar]
- 95.Lee SH, Lee S, Kang H, Lee J, Lee WS. Increased risk of alopecia areata in patients with autism spectrum disorders: a Korean nationwide population-based study. J Am Acad Dermatol. (2023) 89:149–51. doi: 10.1016/j.jaad.2023.01.046 [DOI] [PubMed] [Google Scholar]
- 96.Margari L, Colonna A, Craig F, Gentile M, Giannella G, Lamanna AL, et al. Microphthalmia with linear skin defects (MLS) associated with autism Spectrum disorder (ASD) in a patient with familial 12.9Mb terminal Xp deletion. BMC Pediatr. (2014) 14:220. doi: 10.1186/1471-2431-14-220, PMID: [DOI] [PMC free article] [PubMed] [Google Scholar]
- 97.Afif IY, Manik AR, Munthe K, Maula MI, Ammarullah MI, Jamari J, et al. Physiological effect of deep pressure in reducing anxiety of children with ASD during traveling: a public transportation setting. Bioengineering (Basel). (2022) 9:157. doi: 10.3390/bioengineering9040157, PMID: [DOI] [PMC free article] [PubMed] [Google Scholar]
- 98.Afif IY, Farkhan M, Kurdi O, Maula MI, Ammarullah MI, Setiyana B, et al. Effect of short-term deep-pressure portable seat on behavioral and biological stress in children with autism Spectrum disorders: a pilot study. Bioengineering (Basel). (2022) 9:48. doi: 10.3390/bioengineering9020048, PMID: [DOI] [PMC free article] [PubMed] [Google Scholar]
- 99.Ogawa T, Asayama M, Ito M, Yoshida K. Significance of skin pressure in body heat balance. Jpn J Physiol. (1979) 29:805–16. doi: 10.2170/jjphysiol.29.805, PMID: [DOI] [PubMed] [Google Scholar]
- 100.Foss-Feig JH, Heacock JL, Cascio CJ. Tactile responsiveness patterns and their association with core features in autism spectrum disorders. Res Autism Spectr Disord. (2012) 6:337–44. doi: 10.1016/j.rasd.2011.06.007, PMID: [DOI] [PMC free article] [PubMed] [Google Scholar]
- 101.Wang B, Li YD, Wang ZY, Zhao JQ, Zhang GQ, Man MQ. A Topical Emollient Improves Some Symptoms of Childhood Autism: An Open Label, Randomized Pilot Trial. (Manuscript in preparation).
- 102.Zeidan J, Fombonne E, Scorah J, Ibrahim A, Durkin MS, Saxena S, et al. Global prevalence of autism: a systematic review update. Autism Res. (2022) 15:778–90. doi: 10.1002/aur.2696, PMID: [DOI] [PMC free article] [PubMed] [Google Scholar]
- 103.Mehra A, Arora G, Sahni G, Kaur M, Singh H, Singh B, et al. Gut microbiota and autism Spectrum disorder: from pathogenesis to potential therapeutic perspectives. J Tradit Complement Med. (2022) 13:135–49. doi: 10.1016/j.jtcme.2022.03.001, PMID: [DOI] [PMC free article] [PubMed] [Google Scholar]
- 104.Rylaarsdam L, Guemez-Gamboa A. Genetic causes and modifiers of autism Spectrum disorder. Front Cell Neurosci. (2019) 13:385. doi: 10.3389/fncel.2019.00385, PMID: [DOI] [PMC free article] [PubMed] [Google Scholar]
- 105.Yoon SH, Choi J, Lee WJ, Do JT. Genetic and epigenetic etiology underlying autism Spectrum disorder. J Clin Med. (2020) 9:966. doi: 10.3390/jcm9040966, PMID: [DOI] [PMC free article] [PubMed] [Google Scholar]
- 106.Xie S, Karlsson H, Dalman C, Widman L, Rai D, Gardner RM, et al. The familial risk of autism Spectrum disorder with and without intellectual disability. Autism Res. (2020) 13:2242–50. doi: 10.1002/aur.2417, PMID: [DOI] [PMC free article] [PubMed] [Google Scholar]
- 107.Freed D, Pevsner J. The contribution of mosaic variants to autism Spectrum disorder. PLoS Genet. (2016) 12:e1006245. doi: 10.1371/journal.pgen.1006245, PMID: [DOI] [PMC free article] [PubMed] [Google Scholar]
- 108.Krupp DR, Barnard RA, Duffourd Y, Evans SA, Mulqueen RM, Bernier R, et al. Exonic mosaic mutations contribute risk for autism Spectrum disorder. Am J Hum Genet. (2017) 101:369–90. doi: 10.1016/j.ajhg.2017.07.016, PMID: [DOI] [PMC free article] [PubMed] [Google Scholar]
- 109.Castelbaum L, Sylvester CM, Zhang Y, Yu Q, Constantino JN. On the nature of monozygotic twin concordance and discordance for autistic trait severity: a quantitative analysis. Behav Genet. (2020) 50:263–72. doi: 10.1007/s10519-019-09987-2, PMID: [DOI] [PMC free article] [PubMed] [Google Scholar]
- 110.Li Q, Han Y, Dy ABC, Hagerman RJ. The gut microbiota and autism Spectrum disorders. Front Cell Neurosci. (2017) 11:120. doi: 10.3389/fncel.2017.00120, PMID: [DOI] [PMC free article] [PubMed] [Google Scholar]
- 111.Taniya MA, Chung HJ, Al Mamun A, Alam S, Aziz MA, Emon NU, et al. Role of gut microbiome in autism Spectrum disorder and its therapeutic regulation. Front Cell Infect Microbiol. (2022) 12:915701. doi: 10.3389/fcimb.2022.915701, PMID: [DOI] [PMC free article] [PubMed] [Google Scholar]
- 112.Coury DL, Ashwood P, Fasano A, Fuchs G, Geraghty M, Kaul A, et al. Gastrointestinal conditions in children with autism spectrum disorder: developing a research agenda. Pediatrics. (2012) 130:S160–8. doi: 10.1542/peds.2012-0900N, PMID: [DOI] [PubMed] [Google Scholar]
- 113.de Magistris L, Familiari V, Pascotto A, Sapone A, Frolli A, Iardino P, et al. Alterations of the intestinal barrier in patients with autism spectrum disorders and in their first-degree relatives. J Pediatr Gastroenterol Nutr. (2010) 51:418–24. doi: 10.1097/MPG.0b013e3181dcc4a5, PMID: [DOI] [PubMed] [Google Scholar]
- 114.Borre YE, O'Keeffe GW, Clarke G, Stanton C, Dinan TG, Cryan JF. Microbiota and neurodevelopmental windows: implications for brain disorders. Trends Mol Med. (2014) 20:509–18. doi: 10.1016/j.molmed.2014.05.002, PMID: [DOI] [PubMed] [Google Scholar]
- 115.Kushak RI, Buie TM, Murray KF, Newburg DS, Chen C, Nestoridi E, et al. Evaluation of intestinal function in children with autism and gastrointestinal symptoms. J Pediatr Gastroenterol Nutr. (2016) 62:687–91. doi: 10.1097/MPG.0000000000001174, PMID: [DOI] [PubMed] [Google Scholar]
- 116.De Angelis M, Piccolo M, Vannini L, Siragusa S, De Giacomo A, Serrazzanetti DI, et al. Fecal microbiota and metabolome of children with autism and pervasive developmental disorder not otherwise specified. PLoS One. (2013) 8:e76993. doi: 10.1371/journal.pone.0076993, PMID: [DOI] [PMC free article] [PubMed] [Google Scholar]
- 117.Wang X, Yang J, Zhang H, Yu J, Yao Z. Oral probiotic administration during pregnancy prevents autism-related behaviors in offspring induced by maternal immune activation via anti-inflammation in mice. Autism Res. (2019) 12:576–88. doi: 10.1002/aur.2079, PMID: [DOI] [PubMed] [Google Scholar]
- 118.Hsiao EY, McBride SW, Hsien S, Sharon G, Hyde ER, McCue T, et al. Microbiota modulate behavioral and physiological abnormalities associated with neurodevelopmental disorders. Cells. (2013) 155:1451–63. doi: 10.1016/j.cell.2013.11.024 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 119.Al Bander Z, Nitert MD, Mousa A, Naderpoor N. The gut microbiota and inflammation: an overview. Int J Environ Res Public Health. (2020) 17:7618. doi: 10.3390/ijerph17207618, PMID: [DOI] [PMC free article] [PubMed] [Google Scholar]
- 120.Fiorentino M, Sapone A, Senger S, Camhi SS, Kadzielski SM, Buie TM, et al. Blood-brain barrier and intestinal epithelial barrier alterations in autism spectrum disorders. Mol Autism. (2016) 7:49. doi: 10.1186/s13229-016-0110-z [DOI] [PMC free article] [PubMed] [Google Scholar]
- 121.Molloy CA, Morrow AL, Meinzen-Derr J, Schleifer K, Dienger K, Manning-Courtney P, et al. Elevated cytokine levels in children with autism spectrum disorder. J Neuroimmunol. (2006) 172:198–205. doi: 10.1016/j.jneuroim.2005.11.007 [DOI] [PubMed] [Google Scholar]
- 122.Saghazadeh A, Ataeinia B, Keynejad K, Abdolalizadeh A, Hirbod-Mobarakeh A, Rezaei N. Anti-inflammatory cytokines in autism spectrum disorders: a systematic review and meta-analysis. Cytokine. (2019) 123:154740. doi: 10.1016/j.cyto.2019.154740, PMID: [DOI] [PubMed] [Google Scholar]
- 123.Arteaga-Henríquez G, Gisbert L, Ramos-Quiroga JA. Immunoregulatory and/or anti-inflammatory agents for the Management of Core and Associated Symptoms in individuals with autism Spectrum disorder: a narrative review of randomized. Placebo-Controlled Trials CNS Drugs. (2023) 37:215–29. doi: 10.1007/s40263-023-00993-x, PMID: [DOI] [PMC free article] [PubMed] [Google Scholar]
- 124.Hu L, Mauro TM, Dang E, Man G, Zhang J, Lee D, et al. Epidermal dysfunction leads to an age-associated increase in levels of serum inflammatory cytokines. J Invest Dermatol. (2017) 137:1277–85. doi: 10.1016/j.jid.2017.01.007, PMID: [DOI] [PMC free article] [PubMed] [Google Scholar]
- 125.Ashida Y, Ogo M, Denda M. Epidermal interleukin-1 alpha generation is amplified at low humidity: implications for the pathogenesis of inflammatory dermatoses. Br J Dermatol. (2001) 144:238–43. doi: 10.1046/j.1365-2133.2001.04007.x, PMID: [DOI] [PubMed] [Google Scholar]
- 126.Ashida Y, Denda M. Dry environment increases mast cell number and histamine content in dermis in hairless mice. Br J Dermatol. (2003) 149:240–7. doi: 10.1046/j.1365-2133.2003.05408.x, PMID: [DOI] [PubMed] [Google Scholar]
- 127.Denda M, Sato J, Tsuchiya T, Elias PM, Feingold KR. Low humidity stimulates epidermal DNA synthesis and amplifies the hyperproliferative response to barrier disruption: implication for seasonal exacerbations of inflammatory dermatoses. J Invest Dermatol. (1998) 111:873–8. doi: 10.1046/j.1523-1747.1998.00364.x, PMID: [DOI] [PubMed] [Google Scholar]
- 128.Yang B, Lv C, Ye L, Wang Z, Kim Y, Luo W, et al. Stratum corneum hydration inversely correlates with certain serum cytokine levels in the elderly, possibly contributing to inflammaging. Immun Ageing. (2023) 20:7. doi: 10.1186/s12979-023-00331-1, PMID: [DOI] [PMC free article] [PubMed] [Google Scholar]
- 129.Tikuisis P, Meunier P, Jubenville CE. Human body surface area: measurement and prediction using three dimensional body scans. Eur J Appl Physiol. (2001) 85:264–71. doi: 10.1007/s004210100484, PMID: [DOI] [PubMed] [Google Scholar]
- 130.Elahy M, Jackaman C, Mamo JC, Lam V, Dhaliwal SS, Giles C, et al. Blood-brain barrier dysfunction developed during Normal aging is associated with inflammation and loss of tight junctions but not with leukocyte recruitment. Immun Ageing. (2015) 12:2. doi: 10.1186/s12979-015-0029-9, PMID: [DOI] [PMC free article] [PubMed] [Google Scholar]
- 131.Ye L, Mauro TM, Dang E, Wang G, Hu LZ, Yu C, et al. Topical applications of an emollient reduce circulating pro-inflammatory cytokine levels in chronically aged humans: a pilot clinical study. J Eur Acad Dermatol Venereol. (2019) 33:2197–201. doi: 10.1111/jdv.15540, PMID: [DOI] [PMC free article] [PubMed] [Google Scholar]
- 132.Ye L, Wang Z, Kim Y, Elias PM, Li T, Wen S, et al. A topical emollient mitigates the progression of cognitive impairment in the elderly: a randomized, open-label pilot trial. J Eur Acad Dermatol Venereol. (2022) 36:1382–8. doi: 10.1111/jdv.18162, PMID: [DOI] [PubMed] [Google Scholar]
- 133.Al-Huseini S, Al-Barhoumi A, Al-Balushi M, Al-Hosni A, Al-Mahrouqi T, Al-Mahrizi B, et al. Effectiveness and adverse effects of risperidone in children with autism Spectrum disorder in a naturalistic clinical setting at a University Hospital in Oman. Autism Res Treat. (2022) 2022:1–7. doi: 10.1155/2022/2313851 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 134.Turgay A, Binder C, Snyder R, Fisman S. Long-term safety and efficacy of risperidone for the treatment of disruptive behavior disorders in children with subaverage IQs. Pediatrics. (2002) 110:e34. doi: 10.1542/peds.110.3.e34, PMID: [DOI] [PubMed] [Google Scholar]
- 135.Hon KL, Kung JSC, Ng WGG, Leung TF. Emollient treatment of atopic dermatitis: latest evidence and clinical considerations. Drugs Context. (2018) 7:212530: 1–14. doi: 10.7573/dic.212530 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 136.Techasatian L, Kiatchoosakun P. Effects of an emollient application on newborn skin from birth for prevention of atopic dermatitis: a randomized controlled study in Thai neonates. J Eur Acad Dermatol Venereol. (2022) 36:76–83. doi: 10.1111/jdv.17675 [DOI] [PubMed] [Google Scholar]
- 137.Man MQ, Ye L, Hu L, Jeong S, Elias PM, Lv C. Improvements in epidermal function prevent relapse of psoriasis: a self-controlled study. Clin Exp Dermatol. (2019) 44:654–7. doi: 10.1111/ced.13888, PMID: [DOI] [PubMed] [Google Scholar]
- 138.Seité S, Khemis A, Rougier A, Ortonne JP. Emollient for maintenance therapy after topical corticotherapy in mild psoriasis. Exp Dermatol. (2009) 18:1076–8. doi: 10.1111/j.1600-0625.2009.00903.x, PMID: [DOI] [PubMed] [Google Scholar]
- 139.Fluhr JW, Cavallotti C, Berardesca E. Emollients, moisturizers, and keratolytic agents in psoriasis. Clin Dermatol. (2008) 26:380–6. doi: 10.1016/j.clindermatol.2008.01.015, PMID: [DOI] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Data Availability Statement
The original contributions presented in the study are included in the article/supplementary material, further inquiries can be directed to the corresponding authors.